Searchable abstracts of presentations at key conferences in endocrinology

ea0026p181 | Neuroendocrinology | ECE2011

GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis

Minoia M , Gentilin E , Tagliati F , Mole D , Ambrosio M R , Baroni A , degli Uberti E , Zatelli M C

GH and insulin-like growth factor 1 (IGF1) are known to promote breast carcinogenesis. Breast cancer (BC) incidence in not increased in female acromegalic patients, but mortality is greater as compared to general population. We previously demonstrated that GH/IGF1 excess influences BC response to therapy, possibly accounting for the increased mortality. We indeed showed that GH and IGF1 induce cell proliferation of a BC cell line, the MCF7 cells, providing protection towards t...

ea0026p486 | Thyroid cancer | ECE2011

mTOR inhibition hampers cell viability in selected human medullary thyroid carcinoma primary cultures

Filieri C , Zatelli M C , Minoia M , Tagliati F , Buratto M , Ambrosio M R , Pelizzo M , degli Uberti E C

It has been demonstrated that everolimus, an mTOR inhibitor, has potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures. We aimed at evaluating the possible antiproliferative effects of everolimus in a group of 20 human MTC in primary culture. To this purpose, 20 MTCs were dispersed in primary cultures, treated without or with 1 nM – 1 μM everolimus, 10 nM SOM230, and/or 50 nM IGF1. Cell viab...